Objective (s): Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor,
possesses verified anti-inflammatory and anti-oxidative stress effects against diabetic …

Background Evidence from both animal and human studies clearly supports the renal
beneficial effects of empagliflozin (emp), a sodium glucose co-transporter 2 (SGLT2) …

Hyperglycemia associated with inflammation and oxidative stress is a major cause of
vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a …

Advanced glycation end products (AGEs) and receptor RAGE play a role in diabetic
nephropathy. We have previously shown that increased glucose uptake into proximal …

SGLT2 inhibitor-related nephroprotection is—at least partially—mediated by anti-
inflammatory drug effects, as previously demonstrated in diabetic animal and human …

Sodium–glucose co-transporter 2 inhibitors (iSGLT2) have been linked to a considerable
reduction in cardiovascular risk in patients with type 2 diabetes (T2D), but the precise …

Objective In diabetes, vascular dysfunction is characterized by impaired endothelial function
due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co …

Abstract Sodium‑glucose co‑transporter 2 (SGLT2) inhibitors are recently developed oral
hypoglycemic agents, which act on renal proximal tubules by reducing the reabsorption of …

Background. Recent meta‐analyses have shown that sodium‐glucose cotransporter 2
(SGLT‐2) inhibitors alleviate chronic kidney disease and acute kidney injury in diabetic …

Dapagliflozin, the Sodium-glucose cotransporter 2 (SGLT2) inhibitor class of glucose-
lowering agents, has shown the significantly nephroprotective effects to reduce the risk of …